Veradigm (MDRX) Stock Price, News & Analysis

+0.25 (+3.14%)
(As of 02:26 PM ET)
Today's Range
50-Day Range
52-Week Range
312,063 shs
Average Volume
3.85 million shs
Market Capitalization
$895.93 million
P/E Ratio
Dividend Yield
Price Target

Veradigm MarketRank™ Stock Analysis

Analyst Rating
2.20 Rating Score
46.5% Upside
$11.25 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.44mentions of Veradigm in the last 14 days
Based on 5 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.70 to $0.78 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Business Services Sector

196th out of 306 stocks

Computer Integrated Systems Design Industry

16th out of 34 stocks

MDRX stock logo

About Veradigm Stock (NASDAQ:MDRX)

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

MDRX Stock Price History

MDRX Stock News Headlines

Veradigm (NASDAQ:MDRX) Coverage Initiated at
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Veradigm (NASDAQ:MDRX) Stock Price Up 9.3%
Veradigm (NASDAQ:MDRX) Shares Gap Up to $7.45 Begins Coverage on Veradigm (NASDAQ:MDRX)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
MDRX Apr 2024 2.500 put
Veradigm Completes Acquisition of ScienceIO
Market Whales and Their Recent Bets on MDRX Options
Veradigm Receives Expected Delisting Notice from Nasdaq
Veradigm to Acquire ScienceIO
See More Headlines
Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Computer integrated systems design
Health Care Technology
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$1.50 billion
Cash Flow
$2.85 per share


Free Float
Market Cap
$868.62 million

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. P. Gregory Garrison (Age 70)
    Executive Chairman of the Board
    Comp: $103k
  • Ms. Tejal Vakharia (Age 50)
    Senior VP of Marketing & Government Affairs, General Counsel and Chief Compliance Counsel
    Comp: $1.04M
  • Dr. Shih-Yin Ho M.B.A. (Age 53)
    M.D., Interim Chief Executive Officer & Director
  • Mr. Thomas J. Langan (Age 57)
    President & Chief Commercial Officer
  • Mr. Leland A. Westerfield (Age 54)
    Interim CFO and Principal Financial & Accounting Officer
  • Jenny Gelinas
    Vice President of Investor Relations
  • Mr. Richard Elmore
    Senior Vice President of Corporate Development & Strategy
  • Ms. Lisa Hammond C.P.C. (Age 51)
    Senior VP & Chief Human Resources Officer
  • Mr. John Sage
    Senior Vice President of U.S. Hospitals & Health Systems Sales
  • Mr. Elliot Bryant
    Senior VP & General Manager for Classic Client Solutions Business Unit

MDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Veradigm stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veradigm in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDRX, but not buy additional shares or sell existing shares.
View MDRX analyst ratings
or view top-rated stocks.

What is Veradigm's stock price target for 2024?

5 analysts have issued 1-year price targets for Veradigm's stock. Their MDRX share price targets range from $10.00 to $13.00. On average, they expect the company's share price to reach $11.25 in the next twelve months. This suggests a possible upside of 46.5% from the stock's current price.
View analysts price targets for MDRX
or view top-rated stocks among Wall Street analysts.

How have MDRX shares performed in 2024?

Veradigm's stock was trading at $10.49 at the start of the year. Since then, MDRX stock has decreased by 26.8% and is now trading at $7.68.
View the best growth stocks for 2024 here

How were Veradigm's earnings last quarter?

Veradigm Inc. (NASDAQ:MDRX) posted its quarterly earnings data on Thursday, November, 4th. The software maker reported $0.27 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.09. The software maker had revenue of $369 million for the quarter, compared to analysts' expectations of $376.09 million. Veradigm's revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.15 EPS.

What is Paul Black's approval rating as Veradigm's CEO?

796 employees have rated Veradigm Chief Executive Officer Paul Black on Paul Black has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Veradigm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veradigm investors own include Advanced Micro Devices (AMD), Netflix (NFLX), Energy Transfer (ET), CVS Health (CVS), Ford Motor (F), Himax Technologies (HIMX), Intel (INTC), OPKO Health (OPK), Tesla (TSLA) and Activision Blizzard (ATVI).

Who are Veradigm's major shareholders?

Veradigm's stock is owned by a number of retail and institutional investors. Top institutional investors include Meadow Creek Wealth Advisors LLC (0.01%). Insiders that own company stock include David B Stevens, Elaina Shekhter, Elizabeth Ann Altman, Greg Garrison, Leah Jones, Lisa Khorey, Michael Klayko, Paul Black, Richard J Poulton, Tejal Vakharia and Thomas Langan.
View institutional ownership trends

How do I buy shares of Veradigm?

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veradigm have any subsidiaries?
The following companies are subsidiares of Veradigm: HealthGrid, Practice Fusion, and ZappRx.
Read More
This page (NASDAQ:MDRX) was last updated on 4/24/2024 by Staff

From Our Partners